Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01030640 · ClinicalTrials.gov registry record · Phase 1
Study To Assess Changes In The Number Of Nerves In The Skin At The Site Where Where Tanezumab Is Injected
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT01030640 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 28 participants.
The verdict
NCT01030640, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
Subcutaneous administration of tanezumab can result in changes in the number of nerves around the injection site in the thigh.
Interventions
- OTHER placebo
- BIOLOGICAL tanezumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2009-12 |
| Est. Completion | 2010-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01030640
The ClinicalTrials.gov registry entry for NCT01030640 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT01030640 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01030640 about?
NCT01030640 is a clinical study titled "Study To Assess Changes In The Number Of Nerves In The Skin At The Site Where Where Tanezumab Is Injected". Subcutaneous administration of tanezumab can result in changes in the number of nerves around the injection site in the thigh.
What is the current status of trial NCT01030640?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2009-12. Estimated completion is 2010-09.
What interventions are being tested in trial NCT01030640?
The interventions under investigation include: placebo (OTHER), tanezumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT01030640?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.